---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-042809"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T02:44:40.438361+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents executives take salary reduction; CEO by 35%, others by 15%

## Summary
- CEO Phillip Chan reduces salary by 35% ($123,498) to $359,353 through Dec 31, 2024.
- CFO Kathleen Bloch reduces salary by 15% ($46,587) to $378,413; same for other NEOs.
- Board grants nonqualified stock options equal in value to each reduction at $0.95/share.
- Options vest fully on Jan 31, 2025; expired 10 years from grant date.
- Program aims to cut costs; salaries automatically restore to prior level after 2024.

## SEC filing metadata
- accession: 0001104659-24-042809
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465924042809/0001104659-24-042809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465924042809/tm2410651d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-042809
- JSON: https://secwatch.observer/filing/0001104659-24-042809.json
- Plain text: https://secwatch.observer/filing/0001104659-24-042809.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.